ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,018.39
-0.34%
Dow Jones
37,903.29
0.23%
US Dollar vs MXN
16.9428
-1.22%
Brent Oil
83.615
0.09%
Bitcoin
58,269.78
0.06%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NYSE
  6. Amneal Pharmaceuticals Holding Co (AMRX)

  7. Amneal Pharmaceuticals Holding Co (AMRX) Noticias

AMRX Amneal Pharmaceuticals Holding Co

5.87
0.00 (0.00%)
Fuera de horario
Última actualización: 19:00:00
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Amneal Pharmaceuticals Holding Co AMRX NYSE Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.00 0.00% 5.87 19:00:00
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
5.87 5.87
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
24/4/202407:00BWAmneal Announces U.S. FDA Approval of Over-the-Counter..
16/4/202407:00BWAmneal Launches PEMRYDI RTU®, the First Ready-to-Use Version..
10/4/202407:00BWAmneal to Report First Quarter 2024 Results on May 3, 2024
28/3/202415:05BWAmneal to Ring the Nasdaq Closing Bell on April 2, 2024
25/3/202415:05BWAmneal Receives U.S. FDA Approval for Ciprofloxacin and..
22/3/202407:01EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
22/3/202407:01EDGAR2Form DEF 14A - Other definitive proxy statements
06/3/202416:40EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/3/202416:39EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202415:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/3/202415:35EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01/3/202405:13EDGAR2Form 8-K - Current report
01/3/202405:00BWAmneal Reports Fourth Quarter and Full Year 2023 Financial..
29/2/202415:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/2/202407:00BWAmneal Enters into Exclusive European Licensing Agreement..
13/2/202407:00BWAmneal to Participate at Upcoming Investor Conference
08/2/202415:05GLOBEAmneal Announces Complete Response Resubmission for IPX203..
31/1/202415:05BWAmneal to Report Fourth Quarter and Full Year 2023 Results..
10/1/202407:00BWAmneal Launches Complex Generic Fluorometholone Ophthalmic..
04/1/202415:05BWAmneal Launched Record Number of 39 New Retail and..
26/12/202315:10EDGAR2Form 25 - Notification of the removal from listing and..
26/12/202315:05EDGAR2Form 8-A12B - Registration of securities [Section 12(b)]
21/12/202307:00BWAmneal to Participate at the 42nd Annual J.P. Morgan..
15/12/202315:15EDGAR2Form 8-K - Current report
15/12/202315:06EDGAR2Form 8-K/A - Current report: [Amend]
15/12/202315:05BWAmneal Announces Move to Nasdaq
07/12/202307:00BWAmneal and BIAL Announce U.S. Licensing Agreement for..
01/12/202315:15EDGAR2Form SC 13D/A - General statement of acquisition of..
01/12/202315:15EDGAR2Form 4/A - Statement of changes in beneficial ownership of..
01/12/202307:00BWAmneal Expands Portfolio with Addition of Icosapent Ethyl..
20/11/202305:07EDGAR2Form 15-12G - Securities registration termination [Section..
08/11/202317:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/11/202317:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/11/202317:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/11/202317:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/11/202317:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/11/202316:15EDGAR2Form S-8 POS - Securities to be offered to employees in..
08/11/202316:13EDGAR2Form POS AM - Post-Effective amendments for registration..
08/11/202316:12EDGAR2Form POS AM - Post-Effective amendments for registration..
08/11/202316:07EDGAR2Form SC 13D/A - General statement of acquisition of..
08/11/202316:05EDGAR2Form SC 13D/A - General statement of acquisition of..
08/11/202316:03EDGAR2Form SC 13D/A - General statement of acquisition of..
08/11/202315:59EDGAR2Form SC 13D/A - General statement of acquisition of..
08/11/202315:55EDGAR2Form SC 13D/A - General statement of acquisition of..
08/11/202306:40EDGAR2Form 8-K12B - Notification that a class of securities of..
07/11/202305:21EDGAR2Form 8-K - Current report
07/11/202305:00BWAmneal Reports Third Quarter 2023 Financial Results
03/11/202307:00BWAmneal to Participate at Upcoming Investor Conferences
23/10/202315:16EDGAR2Form 8-K - Current report
23/10/202315:05BWAmneal Reports Certain Preliminary Third Quarter 2023..

Su Consulta Reciente

NYSE
AMRX
Amneal Pharmaceuticals
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados